June 17, 2026 · 19 min read

Slowing aging after 35: what actually works, for women

Abstract. After the age of 35 a woman’s body enters a phase in which body composition, bone density and the hormonal axis begin to change — slowly, and then less slowly, toward perimenopause. It is also the age at which anti-aging marketing gets most aggressive: NAD+ pills, peptides, longevity stacks, “patented” supplements. This article tries to do the one honest thing possible — to rank the interventions not by how new or expensive they are, but by their risk/benefit ratio. The result is awkward for sellers: the things that pay off most (strength training, sleep, protein, diet, not smoking) are free and dull; the most useful and most misunderstood chapter is the hormonal one, which is medicine and has to be managed with a doctor; most supplements correct deficiencies or add at the margin, they don’t replace the basics; and the experimental frontier — metformin, rapamycin, peptides — is interesting science, not a starting point. No miracles, just proportions.

In medicine and nutrition a simple rule often holds: the more something truly works, the less it needs to be sold. The interventions with the best data have a long history, are cheap, and are boring. The ones that fill the ads are almost always the least proven.

I say this upfront because the topic “slowing aging for women 35 and up” is one of the most polluted that exists. There’s an entire industry built on this demographic — aware, informed women with spending power, at the first signs of time passing — and almost everything it proposes is sold backwards relative to what actually pays off.

So let’s try to put things back in order by what matters: how much an intervention gives you, how much it costs you in risk, and who it makes sense for. Four levels, from the most solid to the most experimental.

1. The basics that pay off most and risk almost nothing¶

Let’s start with the part nobody wants to be told, because you can’t buy it at the pharmacy.

Strength training. If I had to name a single intervention for a woman who wants to age well, this would be it, without hesitation. After 35 you lose muscle mass slowly but steadily (sarcopenia), and with menopause bone loss accelerates too. Lifting weights — even two sessions a week, even with modest loads at first — is the only stimulus that acts on both fronts: it preserves muscle and keeps up bone density, reducing the risk of osteoporosis and of the fractures that, in later life, are one of the main events that change the trajectory of a life. Population studies show that muscle-strengthening activities are associated with lower mortality, independently of aerobic activity (Momma, Br J Sports Med, 2022).

You don’t need a complicated program. The World Health Organization guidelines recommend strengthening activity for all the major muscle groups at least two days a week (WHO, 2020); the UK’s National Health Service (NHS) translates that into practice as: 8–12 repetitions make one set, aim for at least two sets per exercise, three is better. A beginner’s structure covering the whole body, two or three times a week, can simply be this:

Movement	Example	What it trains
Leg push	squat, lunges, leg press	thighs, glutes
Hip hinge	light deadlift, hip thrust	posterior chain, glutes
Push (overhead/forward)	push-ups (even against a wall), dumbbell presses	chest, shoulders, triceps
Pull	row, lat pulldown, assisted pull-ups	back, biceps
Carry / core	farmer’s walk, plank	core, stability

You start light, mind your technique, add load when the last reps start to feel easy. Cost: the price of a gym, or zero with bodyweight. Risk: minimal, if technique is decent.

Aerobic capacity. Cardiorespiratory fitness — how efficiently your heart and lungs sustain prolonged effort — is one of the strongest predictors of how long and how well you’ll live. You don’t need to run marathons: the same WHO guidelines point to 150–300 minutes a week of moderate activity (or 75–150 of vigorous) — brisk walking, cycling, swimming, with the occasional harder stretch (WHO, 2020). Strength and aerobic work together cover the vast majority of what exercise can do for longevity.

Protein. With age the body becomes less efficient at using protein to build muscle (it’s called anabolic resistance). That’s why, paradoxically, a 45-year-old woman needs more protein than a twenty-something, not less. The reference meta-analysis on training and protein found that gains in mass and strength stop increasing beyond about 1.6 grams per kilo of body weight per day — roughly double the recommended minimum (Morton, Br J Sports Med, 2018). It’s a population value with a wide margin, not a milligram-precise target: the idea is to aim around 1.6 g/kg spread across meals, not concentrated in the evening. In practice, for a woman of about 65 kg that’s ~100 g of protein a day, for example:

Meal	Example	Protein (approx.)
Breakfast	Greek yogurt + eggs, or ricotta	25–30 g
Lunch	legumes or fish + whole grains	30–35 g
Dinner	chicken, fish or tofu + vegetables	30–35 g
Snack	nuts, a piece of cheese	10–15 g

(The formal recommendations, 1.0–1.5 g/kg, are written for the over-65s — ESPEN, 2014; at 35 the point isn’t the clinical threshold but the trajectory: the habit is built before it’s needed.) It’s the nutritional lever that makes the difference for keeping the muscle that training builds, and it’s the point people get wrong most.

Sleep. Seven to eight hours aren’t a luxury, they’re maintenance. Sleep regulates appetite, insulin sensitivity, inflammation, mood, memory. Perimenopause often disrupts it — night sweats, waking up — and it’s one of the reasons this phase weighs so heavily: it isn’t just the hormone, it’s also the sleep that breaks. Three things, in order of how well proven they are:

The best-evidenced approach to insomnia in this phase is cognitive behavioral therapy for insomnia (CBT-I): sleep hygiene, stimulus control, sleep restriction, in a few sessions. In studies on women in the menopausal transition it improves sleep quality with effects that last over time, and for sleep it works better than drugs, exercise or estrogen (2024 reviews).
When the waking is caused by night sweats, addressing the cause — including, for those who have an indication for it, the hormonal chapter of the paragraph that follows — does more for sleep than any sleeping pill.
Magnesium is popular, but honestly the evidence is weak: the available review shows a small, low-quality effect (Mah & Pitre, 2021). If you try it, put it in the “harmless and maybe a little useful” box, not in the “solutions” box.

Protecting your sleep is worth more than any supplement on the list that follows.

Diet. Without chasing fads: the Mediterranean pattern is the only dietary scheme with clinical data on real outcomes, not just on biomarkers. Vegetables, legumes, fish, olive oil, whole grains, little red meat and very few ultra-processed foods. Not because it’s “magic”, but because it’s the only one that, studied for years in real people, has shown it reduces cardiovascular events.

And the subtractions. Quitting smoking and keeping alcohol to a minimum are, in risk/benefit terms, among the most powerful interventions there are — because they remove harm instead of adding presumed benefit. Alcohol in particular is underestimated by women: it’s associated with an increased risk of breast cancer even at doses the culture considers “moderate”.

This first level doesn’t sell well because it’s free, slow and unexciting. But this is where 70–80% of the result is decided. Everything that comes after only makes sense on top of these foundations, not in their place.

Starter plan, first 30 days. A checklist to begin, without buying anything:

Strength, 2 times a week: the five movements from the table, 2 sets of 8–12 reps, light load and careful technique.

Aerobic: 150 minutes a week spread however you can — even 30 minutes of brisk walking on 5 days.

Protein at every meal: aim for ~1.6 g/kg; start by putting a protein source at breakfast, the meal where it’s usually missing.

Sleep: same wake-up time every day, cool dark bedroom, screens away from the bed. If sweats or waking don’t pass, note them down to discuss with your doctor.

Subtractions: one week without alcohol, to see how your sleep changes. If you smoke, quitting is the number-one lever, above everything else on this list.

Thirty days don’t change a body, but they build the habits everything else rests on.

2. The hormonal chapter: perimenopause and hormone therapy¶

This is the most important point of the article, and it’s also the one on which the most confusion has piled up over the last twenty years.

From 35 up, and especially toward 40, many women enter perimenopause: estrogen begins to fluctuate and then to decline. This isn’t only about hot flashes. Estrogen plays a role in bone, cardiovascular profile, fat distribution, sleep, mood, mucous membranes. Its decline is one of the biological reasons why this phase, for many, is a real watershed and not an imagined one.

A note on timing, because it matters. Perimenopause begins on average between the mid- and late-40s and lasts about four years before periods stop; true menopause arrives on average around 52 (Office on Women’s Health, USA). It can start earlier, even in the mid-30s — but that’s the leading edge, not the norm. That’s why at 35 the point isn’t “to do something”, but to know that the phase exists and when it’s worth talking about it.

The recent history went like this. In 2002 the large Women’s Health Initiative study (Rossouw, JAMA, 2002) raised an alarm about combined hormone therapy, and within a few months a generation of women and doctors abandoned it. The problem is that that result was partly misread: the population studied was on average older (many over 60, far from menopause), and it was later understood that when you start changes everything.

Hence the “window of opportunity” hypothesis: starting hormone therapy close to menopause (roughly under 60, or within 10 years of the last period) has a different, and more favorable, risk/benefit profile than starting it very late. The ELITE study (Hodis, N Engl J Med, 2016) showed that estradiol slowed the progression of atherosclerosis in women in recent menopause, but not in those more than ten years past it. And the long-term analyses of the WHI itself (Manson, JAMA, 2017) found no increase in overall mortality.

What does that mean in practice? That for a woman with symptoms (hot flashes, sleep disturbances, dryness, drop in quality of life) close to menopause and without contraindications, modern hormone therapy — usually transdermal estradiol, i.e. patch or gel, plus progesterone if the uterus is present — has a risk/benefit ratio that today’s menopause societies consider favorable. The most recent guidelines say it clearly: for healthy women with symptoms, under 60 or within 10 years of menopause, the benefits outweigh the risks (The Menopause Society, 2022).

The types of therapy, concretely. “Hormone therapy” isn’t one thing, and the differences matter for risk. The guidelines (The Menopause Society 2022; NICE NG23, UK) distinguish above all:

Choice	Options	What it changes
Estrogen route	transdermal (patch/gel) vs oral (tablet)	the transdermal route does not increase the risk of venous thrombosis; the oral one does, and also raises stroke risk a little. For the same symptoms the transdermal route has the cleaner profile, especially with risk factors or excess weight (NICE NG23)
Progestogen (if uterus present)	micronized progesterone (“body-identical”) vs synthetic progestogens	needed to protect the uterus; in observational data the micronized form seems to have a better profile on the breast — but the guidelines warn that solid evidence from randomized trials to declare it superior is still lacking (NICE NG23)
Dose	the lowest that controls symptoms	less dose, less risk

The practical point: there is no “the hormone”, there are combinations, and the right one depends on you — uterus or not, risk factors, symptoms. It’s a conversation with your doctor, not an off-the-shelf choice.

What it actually does, beyond removing symptoms. Here honesty is needed in three directions, because this is exactly where marketing inflates:

Bone: solid benefit. Hormone therapy prevents bone loss and reduces fractures, and the effect lasts as long as you take it (The Menopause Society 2022; NICE NG23).
Heart: it depends on when you start, and it is NOT a reason to take it. The guidelines are explicit: hormone therapy should not be used to prevent cardiovascular disease (NICE NG23). The “window” hypothesis only says that, started early, cardiovascular risk is low — not that it protects the heart like a treatment.
Brain: not proven, don’t take it for that. There’s no evidence it prevents cognitive decline or dementia; the guidelines say not to prescribe it for this purpose, and if started late (after 65) the risk of dementia might even increase (NICE NG23). It’s exactly the kind of promise the data don’t support.

The risks, with the real numbers. The main fear is the breast: let’s put the proportions in place. Among women aged 50 to 69 who have never used hormone therapy there are about 63 cases of breast cancer per 1000 (roughly 1 in 16). Five years of therapy add, indicatively: ~5 cases per 1000 with estrogen alone, ~14 with cyclic combined, ~20 with continuous combined (MHRA data, 2019); NICE estimates 8–10 extra cases per 1000 for the combined form up to 5 years. The risk grows with duration and decreases after stopping; estrogen-only therapy (for those without a uterus) raises it very little or not at all (The Menopause Society, 2022). To this you add thrombosis and stroke, tied above all to the oral route (see table above).

And on the other side of the scale: hormone therapy remains the most effective treatment for hot flashes and genitourinary symptoms, and for many women with heavy symptoms the difference in quality of life is real and large (The Menopause Society, 2022). It isn’t just about “not increasing mortality”: it’s about improving the days.

But two honest clarifications are needed, in opposite directions. The first: hormone therapy is not an anti-aging drug to take “for longevity” regardless of symptoms. It is medicine for a condition, it has to be personalized, it has real contraindications (history of breast cancer, thrombosis, some cardiovascular conditions) and it has to be managed with a gynecologist or an endocrinologist, not on a do-it-yourself basis. The second, at the opposite end: the blind fear inherited from 2002 took away from many women, for twenty years, a treatment that would have been appropriate for them. The two things coexist.

For a woman who is 35 with menopause still far off, the point here isn’t “to start something”, but to know the map before you get there: to know this phase exists, that it has solutions, and that the decision has to be made with data and with a doctor, not with fear or with enthusiasm.

The right questions to take to your doctor. If you recognize yourself in the symptoms, or just want to understand the map, these are the points worth clarifying with a gynecologist or endocrinologist:

Am I in perimenopause? Which tests are really needed, and which aren’t?

For my symptoms, does hormone therapy make sense? With what expected benefits?

Given my picture (family history, weight, blood pressure, history of thrombosis or cancer), what’s the safest route for me — patch/gel or tablet?

If I have a uterus, which progestogen, and why?

What are my personal risks, in numbers and not in general?

How often do we review the therapy?

3. Supplements: real evidence versus hype¶

Here the ground gets slippery, because it’s where marketing is most aggressive. I’ll try to separate the little that has serious data from the lot that sells dreams.

The ones with reasonable evidence.

Creatine. It’s not just bodybuilder stuff. It’s one of the most studied and safest supplements there is, it costs next to nothing, and in women — especially when combined with strength training — it helps preserve muscle mass and strength with age (Devries and Phillips, Med Sci Sports Exerc, 2014). There are also signals, more preliminary, on cognition and mood. It’s perhaps the only “anti-aging” supplement with a genuinely good risk/benefit ratio.
Vitamin D. It should be corrected if you’re deficient — and many women are, especially at our latitudes in winter — because it’s needed for bone and muscle. But careful: the large VITAL study (Manson, N Engl J Med, 2019) showed that, in those who aren’t deficient, supplementing it reduces neither cancer nor cardiovascular events. So: measure, correct if needed, don’t megadose in the hope of a longevity effect that isn’t there.
Omega-3. VITAL again (N Engl J Med, 2019): modest or no benefit on primary cardiovascular prevention in those who are already well nourished. It makes sense if you eat little fish; it’s not the life insurance policy it’s made out to be.

The ones that sell dreams.

NMN and NR (the “NAD+ boosters”). They’re the anti-aging stars of the moment. The underlying biology is interesting and mice respond. But in humans the few serious trials — including one in pre-diabetic women — show at most the shift of a biomarker (for example insulin sensitivity in muscle), not a benefit on real clinical outcomes, let alone on lifespan. They cost a lot and promise what they haven’t yet demonstrated.
Resveratrol. The red-wine compound that was meant to mimic calorie restriction. In human data it has disappointed, repeatedly. The only ones still talking about it are supplement catalogs.
The longevity “stacks” and patented blends. Proprietary combinations sold at a premium, with rationales built on cell studies or on rodents. Marketing with science’s cover on it.

The practical rule of level 3: supplements serve to correct deficiencies or to add something at the margin on top of solid bases. They don’t buy longevity, and none of them is worth as much as the eight hours of sleep and two weights sessions of level 1.

4. The experimental frontier¶

Here there’s real science, serious labs, and zero reasons to use them today as a baseline strategy. I include them because they’re talked about a lot and because understanding why they’re still a bet is part of mental hygiene on this topic.

Metformin. An old diabetes drug, cheap, with intriguing epidemiology: diabetics who take it seem, in some studies, to get sick and die a little less than you’d expect. Hence the idea — a serious one, backed by researchers like Nir Barzilai — of testing it as an anti-aging drug in the TAME trial (Barzilai, Cell Metab, 2016). But “promising” isn’t “proven”: it’s not approved for this purpose, and there’s at least one signal that it may blunt training adaptations, i.e. interfere with level 1 itself. For a healthy person it’s an off-label bet, not a base.

Rapamycin (and analogues). It’s the drug with the most robust data on lifespan extension in animals (Harrison, Nature, 2009), and small human studies at low intermittent doses have shown interesting effects on the aging immune system (Mannick, 2018). But in humans the long-term longevity and safety data are missing, and it’s an immunosuppressant: not something to play with outside a controlled experimental setting.

Peptides. The wild west of this world: growth-hormone secretagogues, BPC-157, and an ever-expanding list. They are largely unregulated, sold on the grey market, with scarce or absent human safety data. Their risk/benefit ratio, for a healthy woman who simply wants to age well, is unfavorable today: you’re taking on a poorly quantified risk for a poorly demonstrated benefit.

The common thread of level 4 is this: they’re bets, not foundations. They have their place in research and, in some cases, in highly personalized, closely followed paths. But anyone who starts here — skipping levels 1 and 2 — is making exactly the mistake that anti-aging marketing encourages.

In conclusion¶

If you look at how the anti-aging market is built, you notice one thing: it sells mostly levels 3 and 4 — pills, peptides, stacks — because those are where the margin is. Nobody opens a company to tell you to sleep eight hours and lift two barbells a week.

And yet, if you rank everything by risk/benefit ratio, the picture flips. The biggest return, for a woman 35 and up, is in the most boring and nearly free things: strength, aerobic work, protein, sleep, diet, not smoking. Just above that is the hormonal chapter, which is the most powerful and the most misunderstood, but is medicine and has to be done with a doctor, at the right time and for those who genuinely need it. Supplements serve to correct deficiencies and little more. The experimental frontier is fascinating, but it’s a bet, not a starting point.

Slowing aging, after 35, is less spectacular than they tell you — and much more effective. Not because there’s a secret formula, but because the one that works isn’t secret at all: it’s just not very profitable to sell.

One last note, due and not pro forma. This is an informational article, not personalized medical advice: the doses, protocols and schemes above are general examples, useful for grasping the order of magnitude, not prescriptions tailored to you. Every choice — especially the hormonal one, but also supplements and anything from levels 3 and 4 — has to be made with your own doctor, on your own clinical picture, with contraindications and personal history in hand. Nothing you’ve read replaces that conversation. What I hope stays with you is the method: in front of every promise, always ask yourself how much it pays, how much I risk, and for whom.

Essential bibliography¶

Momma H et al. (2022). Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: a systematic review and meta-analysis of cohort studies. Br J Sports Med. PMID 35228201.
Writing Group for the Women’s Health Initiative Investigators (Rossouw JE et al., 2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the WHI randomized controlled trial. JAMA. PMID 12117397.
Hodis HN et al. (2016). Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol (ELITE). N Engl J Med. PMID 27028912.
Manson JE et al. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The WHI Randomized Trials. JAMA. PMID 28898378.
Devries MC, Phillips SM (2014). Creatine supplementation during resistance training in older adults — a meta-analysis. Med Sci Sports Exerc. PMID 24576864.
Manson JE et al. (2019). Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease (VITAL). N Engl J Med. PMID 30415629.
Manson JE et al. (2019). Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL). N Engl J Med. PMID 30415637.
Barzilai N et al. (2016). Metformin as a Tool to Target Aging (TAME). Cell Metab. PMID 27304507.
Harrison DE et al. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. PMID 19587680.
Mannick JB et al. (2018). TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med. PMID 30021824.
Morton RW et al. (2018). A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength. Br J Sports Med. PMID 28698222.
Deutz NEP et al. (2014). Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr. PMID 24814383.
Bull FC et al. (2020). World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. PMID 33239350.
NHS. Physical activity guidelines for adults aged 19 to 64. nhs.uk.
Mah J, Pitre T (2021). Oral magnesium supplementation for insomnia in older adults: a systematic review and meta-analysis. BMC Complement Med Ther. PMC8053283.
Lee J et al. (2024). Cognitive Behavioral Therapy for Insomnia in menopausal women: a scoping review. Life (Basel). PMC11595697.
The North American Menopause Society (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. PMID 35797481.
National Institute for Health and Care Excellence (NICE). Menopause: diagnosis and management (NG23). nice.org.uk/guidance/ng23.
Office on Women’s Health (U.S. Dept. of Health & Human Services). Menopause basics. womenshealth.gov.